{"contentid": 488491, "importid": NaN, "name": "More I-O early approvals bear scrutiny of FDA review", "introduction": "There was more good news for Swiss company Roche on Wednesday, as the US regulator\u00e2\u0080\u0099s scientific panel voted to maintain another Accelerated Approval for Tecentriq (atezolizumab).", "content": "<p><span style=\"font-weight: 400;\">There was more good news for Swiss company Roche (ROG: SIX) on Wednesday, as the US regulator&rsquo;s scientific panel voted to maintain another Accelerated Approval for Tecentriq (atezolizumab).</span></p>\n<p><span style=\"font-weight: 400;\">The panel voted 10 to one in favor of keeping the approval, despite a lack of confirmatory data, for certain people with locally advanced or metastatic urothelial carcinoma, or bladder cancer.</span></p>\n<p><span style=\"font-weight: 400;\">On Tuesday the panel </span><a href=\"https://www.thepharmaletter.com/article/tecentriq-approval-on-safer-ground-after-fda-panel-vote\"><span style=\"font-weight: 400;\">voted to keep</span></a><span style=\"font-weight: 400;\"> another such early approval in place for the checkpoint blocker, in breast cancer. The Food and Drug Administration is expected to follow the recommendations.</span></p>\n<p><span style=\"font-weight: 400;\">Chief medical officer Levi Garraway said the vote &ldquo;reaffirms that Tecentriq fills a significant unmet need for people with previously untreated metastatic bladder cancer, many of whom cannot tolerate standard of care chemotherapy and need additional options.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">It is unclear whether the FDA will continue to make the approval contingent upon the receipt of specific confirmatory data in future.</span></p>\n<p><span style=\"font-weight: 400;\">Dr Garraway said the company would &ldquo;continue to work with the FDA on next steps for Tecentriq in these indications.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">Global revenues for Tecentriq in 2020 hit 2.7 billion Swiss francs ($2.9 billion), a 55% upswing compared with the prior year.</span></p>\n<h2><strong>Keytruda also in spotlight</strong></h2>\n<p><span style=\"font-weight: 400;\">The US FDA&rsquo;s scientific advisors are </span><a href=\"https://www.thepharmaletter.com/article/us-fda-tightens-ship-on-accelerated-approval-scheme\"><span style=\"font-weight: 400;\">looking again</span></a><span style=\"font-weight: 400;\"> at a range of Accelerated Approvals for which confirmatory data has not been forthcoming.</span></p>\n<p><span style=\"font-weight: 400;\">The review has led a number of drugmakers to voluntarily withdraw products from specific indications, including Keytruda (pembrolizumab), from Merck &amp; Co (NYSE: MRK), Imfinzi (durvalumab), from AstraZeneca (LSE: AZN) and Opdivo (nivolumab), from Bristol Myers Squibb (NYSE: BMY).</span></p>\n<p><span style=\"font-weight: 400;\">On Wednesday, the FDA panel also voted to maintain a conditional approval for Keytruda in metastatic urothelial carcinoma, by a narrower margin of five to three.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">On Thursday, the final day of the panel&rsquo;s discussions, attention will turn to the product&rsquo;s approvals in hepatocellular carcinoma and gastric cancer, as well as an approval for Bristol Myers Squibb's Opdivo in liver cancer.</span></p>", "date": "2021-04-29 10:12:00", "meta_title": NaN, "meta_keywords": "approval, voted, panel, Tecentriq, cancer, company, Accelerated, Swiss, approvals, scientific, maintain, Wednesday, confirmatory, data, metastatic, early", "meta_description": "There was more good news for Swiss company Roche on Wednesday, as the US regulator\u00e2\u0080\u0099s scientific panel voted to maintain another Accelerated Approval for Tecentr", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-29 09:38:58", "updated": "2021-04-29 10:12:14", "access": NaN, "url": "https://www.thepharmaletter.com/article/more-i-o-early-approvals-bear-scrutiny-of-fda-review", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "fda_big.jpg", "image2id": "fda_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "Drug Trial, Focus On, Regulation, Research, US FDA", "geography_tag": "Switzerland, USA", "company_tag": "Bristol-Myers Squibb, Genentech, Merck & Co, Roche", "drug_tag": "Keytruda, Opdivo, Tecentriq", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-29 10:12:00"}